In 2019, the imidazo[1,2-a]pyrazines 9 and 10 were identified by virtual screening from natural resources as CDK9 inhibitors with IC50 values of 7.88 and 5.12 μM, respectively, and evaluated as anticancer agents against breast cancer [27]. This evidence concerns the gene CDK9 and breast carcinoma.